Skip to main content

Gossamer Bio, Inc.

For the period ended Mar 31, 2025. Filed May 15, 2025.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2025 · Filed May 15, 2025

GOSS$11.28+6.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Statements of Stockholders’ Equity (Deficit)

(in thousands, except share amounts)

Common stock · Additional paid-in capital · Accumulated deficit · Accumulated other comprehensive income (loss) · Total stockholders' equity (deficit)
Shares · Amount
Balance as of December 31, 2024226,604,138$23$1,296,848$(1,268,568)$1,189$29,492
Exercise of stock options112,617—132——132
Stock-based compensation——2,405——2,405
Issuance of common stock pursuant to Employee Stock Purchase Plan504,507—372——372
Net loss———(36,638)—(36,638)
Other comprehensive loss————(2,013)(2,013)
Balance as of March 31, 2025227,221,262$23$1,299,757$(1,305,206)$(824)$(6,250)
Common stock · Additional paid-in capital · Accumulated deficit · Accumulated other comprehensive loss · Total stockholders' equity
Shares · Amount
Balance as of December 31, 2023225,409,315$23$1,275,136$(1,212,040)$(350)$62,769
Stock-based compensation——5,811——5,811
Issuance of common stock pursuant to Employee Stock Purchase Plan390,246—348——348
Issuance of common stock for restricted stock units vested419,092—————
Net loss———(41,928)—(41,928)
Other comprehensive income————(278)(278)
Balance as of March 31, 2024226,218,653$23$1,281,295$(1,253,968)$(628)$26,722
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.